Increased fetal hemoglobin (HbF) in erythroid precursors of patients with β-hemoglobinopathies (sickle cell anemia and β-thalassemia), in which adult hemoglobin synthesis is defective, ameliorates the clinical symptoms of the underlying diseases. The production of erythroid precursors depends on the action of erythropoietin (EPO), which prevents their apoptosis and stimulates their proliferation. EPO binds to its surface receptor, induces its homodimerization, and initiates a cascade of phosphorylation and dephosphorylation of a series of proteins by kinases and phosphatases, respectively. Vanadate inhibits various phosphatases, including those that are involved in the EPO pathway, thereby intensifying the signal.
In this study, we investigated the effect of vanadate on the proliferation and maturation of human erythroid precursors in culture. When vanadate was added to cells derived from normal donors, cell maturation was delayed, as indicated by cell morphology, cell growth kinetics, the rate of appearance of hemoglobin-containing cells, and the expression of surface antigens (CD117, CD71, and glycophorin A). Analysis by high-performance liquid chromatography and flow cytometry of the hemoglobin profile of vanadate-treated normal cells revealed a higher proportion of HbF than was found in untreated cells. When vanadate was added to cells derived from patients with β-thalassemia, a significant increase in HbF was observed.
The results suggest that intensification of the EPO signal by vanadate results in maturation arrest and increased HbF production. Thus, inhibitors that are more specific and less toxic than vanadate may present a novel option for elevating HbF in patients with β-hemoglobinopathies, as well as for intensifying the EPO response in other forms of anemia.
Get full access to this article
View all access options for this article.
References
1.
Stamatoyannopoulos G, Grosveld F. Hemoglobin switching. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, Eds. The Molecular Basis of Blood Diseases (3rd ed). Philadelphia: W.B. Saunders Company, pp135–182, 2001.
2.
Weatherall DJ, Edwards JA, Donohoe WT. Haemoglobin and red cell enzyme changes in juvenile myeloid leukaemia. Br Med J1:679–681, 1968.
3.
Alter BP. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol7(Suppl 5):200–209, 1979.
4.
Al-Awamy BH, Niazi GA, el-Mouzan MI, Altorki MT, Naeem MA. Relationship of haemoglobin F and alpha thalassaemia to severity of sickle-cell anaemia in the Eastern Province of Saudi Arabia. Ann Trop Paediatr6:261–265, 1986.
5.
Haghshenass M, Ismail-Beigi F, Clegg JB, Weatherall DJ. Mild sickle-cell anaemia in Iran associated with high levels of fetal haemoglobin. J Med Genet14:168–171, 1977.
6.
Benesch RE, Edalji R, Benesch R, Kwong S. Solubilization of hemoglobin S by other hemoglobins. Proc Natl Acad Sci U S A77: 5130–5134, 1980.
7.
Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med318:96–99, 1988.
8.
Eaton WA, Hofrichter J. The biophysics of sickle cell hydroxyurea therapy. Science268:1142–1143, 1995.
9.
Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe beta-globin disorders. Br J Haematol91:263–268, 1995.
10.
Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A80:4842–4846, 1983.
11.
McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. Induction of gamma-globin by histone deacetylase inhibitors. Blood90:2075–2083, 1997.
12.
Hudgins WR, Fibach E, Safaya S, Rieder RF, Miller AC, Samid D. Transcriptional upregulation of gamma-globin by phenylbutyrate and analogous aromatic fatty acids. Biochem Pharmacol52:1227–1233, 1996.
13.
Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Miller BA, Nathan DG. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest75:1999–2005, 1985.
14.
Torrealba-de Ron AT, Papayannopoulou T, Knapp MS, Fu MF, Knitter G, Stamatoyannopoulos G. Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine. Blood63:201–210, 1984.
15.
Humphries RK, Dover G, Young NS, Moore JG, Charache S, Ley T, Nienhuis AW. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest75:547–557, 1985.
16.
Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev72:449–489, 1992.
17.
Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood77:2583–2590, 1991.
18.
Watowich SS, Liu KD, Xie X, Lai SY, Mikami A, Longmore GD, Goldsmith MA. Oligomerization and scaffolding functions of the erythropoietin receptor cytoplasmic tail. J Biol Chem274:5415–5421, 1999.
19.
Shinjo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assay. Br J Haematol96: 551–558, 1997.
20.
Klingmuller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells–signals emanating from the erythropoietin receptor. Eur J Biochem249:637–647, 1997.
21.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7:387–397, 2005.
22.
Cohen J, Altaratz H, Zick Y, Klingmuller U, Neumann D. Phosphorylation of erythropoietin receptors in the endoplasmic reticulum by pervanadate-mediated inhibition of tyrosine phosphatases. Biochem J327(Pt 2):391–397, 1997.
23.
Fibach E, Manor D, Oppenheim A, Rachmilewitz EA. Proliferation and maturation of human erythroid progenitors in liquid culture. Blood73: 100–103, 1989.
24.
Fibach E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. Hemoglobin22:445–458, 1998.
25.
Kutlar F, Kutlar A, Nuguid E, Prchal J, Huisman TH. Usefulness of HPLC methodology for the characterization of combinations of the common beta chain variants Hbs S, C, and O-Arab, and the alpha chain variant Hb G-Philadelphia. Hemoglobin17:55–66, 1993.
26.
Amoyal I, Goldfarb A, Fibach E. Flow cytometric analysis of hydroxyurea effects on fetal hemoglobin production in cultures of beta-thalassemia erythroid precursors. Hemoglobin27:77–87, 2003.
27.
Amoyal I, Fibach E. Flow cytometric analysis of fetal hemoglobin in erythroid precursors of beta-thalassemia. Clin Lab Haematol26:187–193, 2004.
28.
Fibach E, Rachmilewitz EA. Flow cytometric analysis of the ploidy of normoblasts in the peripheral blood of patients with beta-thalassemia. Am J Hematol42:162–165, 1993.
29.
Wojda U, Leigh KR, Njoroge JM, Jackson KA, Natarajan B, Stitely M, Miller JL. Fetal hemoglobin modulation during human erythropoiesis: stem cell factor has “late” effects related to the expression pattern of CD117. Blood101:492–497, 2003.
30.
Spivak JL, Fisher J, Isaacs MA, Hankins WD. Protein kinases and phosphatases are involved in erythropoietin-mediated signal trans-duction. Exp Hematol20:500–504, 1992.
31.
Lawson AE, Bao H, Wickrema A, Jacobs-Helber SM, Sawyer ST. Phosphatase inhibition promotes antiapoptotic but not proliferative signaling pathways in erythropoietin-dependent HCD57 cells. Blood96:2084–2092, 2000.
32.
Dai CH, Krantz SB, Sawyer ST. Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood89:3574–3581, 1997.
33.
Vinals F, McKenzie FR, Pouyssegur J. Growth factor-stimulated protein synthesis is inhibited by sodium orthovanadate. Eur J Biochem268:2308–2314, 2001.
34.
Dalyot N, Fibach E, Rachmilewitz EA, Oppenheim A. Adult and neonatal patterns of human globin gene expression are recapitulated in liquid cultures. Exp Hematol20:1141–1145, 1992.
35.
Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL. Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Ann Hematol80:492–495, 2001.
36.
Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. J Matern Fetal Med8:1–7, 1999.
37.
Rachmilewitz EA, Goldfarb A, Dover G. Administration of erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Blood78:1145–1147, 1991.
Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, Nagel RL. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood80:3258–3260, 1992.
40.
Al-Khatti A, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med317:415–420, 1987.
41.
Stamatoyannopoulos G, Umemura T, al-Khatti A, Spadaccino E, Abels RI, Fritsch EF, Papayannopoulou T. Modulation of HBF production by erythropoietin. Prog Clin Biol Res 316B:269–280, 1989.
42.
Miller BA, Perrine SP, Bernstein A, Lyman SD, Williams DE, Bell LL, Olivieri NF. Influence of steel factor on hemoglobin synthesis in sickle cell disease. Blood79:1861–1868, 1992.
43.
Peschle C, Gabbianelli M, Testa U, Pelosi E, Barberi T, Fossati C, Valtieri M, Leone L. c-kit ligand reactivates fetal hemoglobin synthesis in serum-free culture of stringently purified normal adult burst-forming unit-erythroid. Blood81:328–336, 1993.
44.
Muta K, Krantz SB, Bondurant MC, Dai CH. Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation. Blood86:572–580, 1995.
45.
Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood105: 387–393, 2005.
46.
Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem153:217–231, 1995.
47.
Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab80:3311–3320, 1995.
